Hessmann Philipp, Zeidler Jan, Stahmeyer Jona, Eberhard Sveja, Vogelgsang Jonathan, Abdel-Hamid Mona, Wolff-Menzler Claus, Wiltfang Jens, Kis Bernhard
Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, Goettingen, Germany.
Center for Health Economics Research Hannover (CHERH), Leibniz University Hannover, Hannover, Germany.
Front Pharmacol. 2019 Jul 24;10:841. doi: 10.3389/fphar.2019.00841. eCollection 2019.
A restrictive use of tricyclic antidepressants (TCA) in patients with dementia (PwD) is recommended due to the hazard of anticholinergic side effects. We evaluated the frequency of TCA dispensing in PwD over a period of 1 year and the use of TCA before and after the incident diagnosis of dementia. This analysis was based on administrative data from a German statutory health insurance for a period of 2 years. Totally, 20,357 patients with an incident diagnosis of dementia in 2014 were included. We evaluated the dispensing of TCA in 2015. Subgroup analyses were conducted to evaluate associations between the incident diagnosis of dementia and modifications in TCA dispensing. In 2015, 1,125 dementia patients (5.5%) were treated with TCA and 31% were medicated with TCA in all four quarters of 2015. Most dispensings were conducted by general practitioners (67.9%). On average, patients received 3.7 ± 2.6 dispensings per year. Amitriptyline (56.3%), doxepin (26.8%), and trimipramine (16.8%) were dispensed most often. Subgroup analyses revealed that the dispensing of TCA remained mainly unchanged following the incident diagnosis. A relevant number of PwD were treated with TCA. To maintain the patients' safety, an improved implementation of guidelines for the pharmaceutical treatment of PwD in healthcare institutions might be required. Since 68% of the patients suffered from depression, future studies should further evaluate the indications for TCA.
由于存在抗胆碱能副作用风险,建议对痴呆症患者(PwD)限制使用三环类抗抑郁药(TCA)。我们评估了1年内PwD患者中TCA的配药频率以及痴呆症确诊前后TCA的使用情况。该分析基于德国法定医疗保险2年期间的管理数据。总共纳入了2014年确诊的20357例痴呆症患者。我们评估了2015年TCA的配药情况。进行亚组分析以评估痴呆症确诊与TCA配药变化之间的关联。2015年,1125例痴呆症患者(5.5%)接受了TCA治疗,31%的患者在2015年的四个季度均使用了TCA。大多数配药由全科医生进行(67.9%)。患者平均每年接受3.7±2.6次配药。最常配出的药物是阿米替林(56.3%)、多塞平(26.8%)和曲米帕明(16.8%)。亚组分析显示,确诊后TCA的配药情况基本保持不变。相当数量的PwD患者接受了TCA治疗。为确保患者安全,可能需要在医疗机构更好地实施PwD药物治疗指南。由于68%的患者患有抑郁症,未来研究应进一步评估TCA的用药指征。